{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:32:30Z","timestamp":1774121550701,"version":"3.50.1"},"reference-count":14,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            New gamma interferon (IFN-\u03b3) release assays (IGRAs) to detect an exposure to\n            <jats:italic>Mycobacterium tuberculosis<\/jats:italic>\n            have recently been launched. The majority of the studies in temperate-climate countries agree that these methods have superior specificity and equal or even superior sensitivity over tuberculin skin tests (TSTs) in the diagnosis of latent tuberculosis (TB) infection (LTBI). However, reproducibility data of IGRAs are virtually missing. We assessed within-run, between-run, and total imprecision of two commercial IGRAs by testing samples from subjects with a stable state of TB infection or treated pulmonary TB, a sample from a healthy volunteer, and internal quality control samples. We calculated coefficients of variance (CV%s) to describe assays variability and compared the obtained results to the reported CV%s for other commercial immunodiagnostic methods. We illustrate an example of assay variability near the cutoff zone to demonstrate the necessity of a gray zone. Due to the strict adherence to the standard operation procedures (SOP) adopted in our laboratory, the total imprecision of enzyme-linked immunospot (ELISPOT)- and enzyme immunoassay (EIA)-based IGRAs was at a maximum CV% of 37.8% for the samples with moderate and high reactivities. Imprecision of testing samples with very low reactivity levels or nonreactive samples may, however, exceed 100%. In conclusion, despite multiple steps of the method performance, the analytical imprecision of IGRAs, which in our study design included also between-lot variability and had a component of normal biological variation, was well in accordance with the reported imprecisions of other manual immunodiagnostic tests. The recognition of the variability around the cutoff point advocates the use of a gray zone to avoid ambiguous result interpretations.\n          <\/jats:p>","DOI":"10.1128\/cvi.00320-09","type":"journal-article","created":{"date-parts":[[2010,2,25]],"date-time":"2010-02-25T04:53:32Z","timestamp":1267073612000},"page":"596-601","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":18,"title":["Assessment of Imprecision in Gamma Interferon Release Assays for the Detection of Exposure to\n            <i>Mycobacterium tuberculosis<\/i>"],"prefix":"10.1128","volume":"17","author":[{"given":"Tamara","family":"Tuuminen","sequence":"first","affiliation":[{"name":"Haartman Institute, University of Helsinki, Department of Bacteriology and Immunology, PL21, Fl-00014 Helsinki, Finland"},{"name":"Division of Clinical Microbiology, Helsinki University Hospital, HUSLAB, Haartmaninkatu 3, P.O. Box 400, Fl-00029 HUS, Helsinki, Finland"},{"name":"Helsinki University Hospital, HUSLAB, Administration Department, Paciuksenkatu 29, P.O. Box 720, Fl-00029 HUS, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esko","family":"Tavast","sequence":"additional","affiliation":[{"name":"Haartman Institute, University of Helsinki, Department of Bacteriology and Immunology, PL21, Fl-00014 Helsinki, Finland"},{"name":"Division of Clinical Microbiology, Helsinki University Hospital, HUSLAB, Haartmaninkatu 3, P.O. Box 400, Fl-00029 HUS, Helsinki, Finland"},{"name":"Helsinki University Hospital, HUSLAB, Administration Department, Paciuksenkatu 29, P.O. Box 720, Fl-00029 HUS, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riitta","family":"Va\u0308isa\u0308nen","sequence":"additional","affiliation":[{"name":"Haartman Institute, University of Helsinki, Department of Bacteriology and Immunology, PL21, Fl-00014 Helsinki, Finland"},{"name":"Division of Clinical Microbiology, Helsinki University Hospital, HUSLAB, Haartmaninkatu 3, P.O. Box 400, Fl-00029 HUS, Helsinki, Finland"},{"name":"Helsinki University Hospital, HUSLAB, Administration Department, Paciuksenkatu 29, P.O. Box 720, Fl-00029 HUS, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaakko-Juhani","family":"Himberg","sequence":"additional","affiliation":[{"name":"Haartman Institute, University of Helsinki, Department of Bacteriology and Immunology, PL21, Fl-00014 Helsinki, Finland"},{"name":"Division of Clinical Microbiology, Helsinki University Hospital, HUSLAB, Haartmaninkatu 3, P.O. Box 400, Fl-00029 HUS, Helsinki, Finland"},{"name":"Helsinki University Hospital, HUSLAB, Administration Department, Paciuksenkatu 29, P.O. Box 720, Fl-00029 HUS, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilkka","family":"Seppa\u0308la\u0308","sequence":"additional","affiliation":[{"name":"Haartman Institute, University of Helsinki, Department of Bacteriology and Immunology, PL21, Fl-00014 Helsinki, Finland"},{"name":"Division of Clinical Microbiology, Helsinki University Hospital, HUSLAB, Haartmaninkatu 3, P.O. Box 400, Fl-00029 HUS, Helsinki, Finland"},{"name":"Helsinki University Hospital, HUSLAB, Administration Department, Paciuksenkatu 29, P.O. Box 720, Fl-00029 HUS, Helsinki, Finland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","unstructured":"Advia 60 manual. 2003"},{"key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1086\/381754","volume":"38","year":"2004","unstructured":"Carrara, S., D. Vincenti, N. Petrosillo, M. Amicosante, E. Girardi, and D. Goletti. 2004. Use of T cell-based assay for monitoring efficacy of anti-tuberculosis therapy. Clin. Infect. Dis.38:754-756.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00168-09"},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"e4130","DOI":"10.1371\/journal.pone.0004130","volume":"4","year":"2009","unstructured":"Herrmann, J.-L., M. Belloy, R. Porcher, N. Simonney, R. Aboutaam, M. Lebourgeois, J. Gaudelus, L. De Losangeles, K. Chadelat, P. Schneinmann, N. Beydon, B. Fauroux, M. Bingen, M. Terki, D. Barraud, P. Cruaud, C. Offredo, A. Ferroni, P. Berche, D. Moissenet, H. Vuthien, C. Doit, E. Bingen, and P. H. Lagrange. 2009. Temporal dynamics of interferon gamma responses in children evaluated for tuberculosis. PLoS One4:e4130.","journal-title":"PLoS One"},{"key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jim.2004.06.008","volume":"291","year":"2004","unstructured":"Janetzki, S., S. Schaed, N. E. Blachere, L. Ben-Porat, A. N. Houghton, and K. S. Panageas. 2004. Evaluation of elispot assays: influence of method and operator on variability of results. J. Immunol. Methods291:175-183.","journal-title":"J. Immunol. Methods"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/clinchem\/30.2.290","volume":"30","year":"1984","unstructured":"Krouwer, J. S., and R. Rabinowitz. 1984. How to improve estimates of imprecision. Clin. Chem.30:290-292.","journal-title":"Clin. Chem."},{"key":"e_1_3_2_8_2","first-page":"340","volume":"14","year":"2007","unstructured":"Menzies, D., M. Pai, and G. Comstock. 2007. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann. Intern. Med.14:340-354.","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_2_9_2","unstructured":"T-SPOT.TB package insert. 2009"},{"key":"e_1_3_2_10_2","first-page":"e208","volume":"4","year":"2007","unstructured":"Pai, M., and R. O'Brien. 2007. Serial testing for tuberculosis: can we make sense of T cell assay conversions and reversions. PLoS One4:e208.","journal-title":"PLoS One"},{"key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.7326\/0003-4819-149-3-200808050-00241","volume":"149","year":"2008","unstructured":"Pai, M., A. Zwerling, and D. Menzies. 2008. Systematic review: T-cell-based assays for the diagnostics of latent tuberculosis infection: an update. Ann. Intern. Med.149:177-184.","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_2_12_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1756-0500-2-9","volume":"2","year":"2009","unstructured":"Tavast, E., I. Sepp\u00e4l\u00e4, E. Salo, and T. Tuuminen. 2009. IGRA tests perform similarly to TST but cause no adverse reactions: pediatric experience in Finland. BMC Res. Notes2:9.","journal-title":"BMC Res. Notes"},{"key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/nrmicro1570","volume":"4","year":"2006","unstructured":"The TDR Diagnostics Evaluation Expert Panel. 2006. Evaluation of diagnostic tests for infectious diseases: general principles. Nat. Rev. Microbiol.4:S20-S32.","journal-title":"Nat. Rev. Microbiol."},{"key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/j.1469-0691.2007.01750.x","volume":"13","year":"2007","unstructured":"Tuuminen, T., S. Sorva, K. Liippo, T. Vasankari, H. Soini, B. Eriks\u00e9n-Neuman, A. Miettinen, and I. Sepp\u00e4l\u00e4. 2007. Feasibility aspects of commercial interferon (IFN)-\u03b3 based methods for the diagnosis of latent Mycobacterium tuberculosis infection in Finland, a country of low incidence and high BCG vaccination coverage. Clin. Microb. Infect.13:836-838.","journal-title":"Clin. Microb. Infect."},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"e1850","DOI":"10.1371\/journal.pone.0001850","volume":"3","year":"2008","unstructured":"Veerapathran, A., R. Joshi, K. Goswami, S. Dogra, E. E. Modie, M. V. Reddy, S. Kalantri, K. Schwartzman, M. A. Behr, D. Menzies, and M. Pai. 2008. T-cell assays for tuberculosis infection: deriving cutoffs for conversion using reproducibility data. PLoS One3:e1850.","journal-title":"PLoS One"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00320-09","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00320-09","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:43:33Z","timestamp":1627591413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00320-09"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1128\/CVI.00320-09"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00320-09","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"2009-08-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2010-01-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-18","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}